• Historia o sospecha de cáncer de mama
• Tumores dependiente de estrógenos conocidos o sospechados (p. ej. cáncer de endometrio),
• Tromboembolismo idiopático previo o actual (trombosis venosa profunda, embolismo pulmonar)
• Enfermedad arterial tromboembólica activa o reciente (angina, infarto de miocardio)
• Enfermedad hepática aguda o historia de enfermedad hepática mientras las pruebas de función hepática retornan a la normalidad • Hipersensibilidad conocida a alguno de sus componentes
• Porfiria
• Diagnóstico o sospecha de embarazo
referencias
1. Miller VT, Muesing RA, LaRosa JC, Stoy DB, Philips EA, Stillman RJ. Effects of conjugated equine estrogen with and without three different progestogens on lipoproteins, high- density lipoprotein subfractions and apolipoprotein A-I. Obstet Gynecol 1991;77:235-240.
2. Whitehead MI, Hillard TC, Crook D. The role and use of progestogens. Obstet Gynecol 1990;75(Suppl.):S59-S76. 3. van de Weijer PHM, Barentsen R,
Kenemans P. Women’s expectations and acceptance of cyclic induced HRT bleeds. Maturitas 1998;30:257-263. 4. Ettinger B, Pressman A, Silver P.
Effect of age on reasons for initiation and discontinuation of hormone replacement therapy. Menopause 1999;6:282- 289.
5. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/ progestin Replacement Study (HERS) Research Group. J Am Med Ass 1998;280:605-613.
6. Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results. From the Women’s Health Initiative randomized controlled trial. J Am Med Ass 2002;288:321-333. 7. Anderson GL, Limacher M, Assaf
AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, Chlebowski R, Curb D, Gass M, Hays J, Heiss G, Hendrix S, Howard BV, Hsia J, Hubbell A, Jackson R, Johnson KC, Judd H, Kotchen JM, Kuller L, LaCroix AZ, Lane D, Langer RD, Lasser N, Lewis CE, Manson J, Margolis K, Ockene J,
O’Sullivan MJ, Phillips L, Prentice RL, Ritenbaugh C, Robbins J, Rossouw JE, Sarto G, Stefanick ML, Van Horn L, Wactawski-Wende J, Wallace R, Wassertheil-Smoller S. Women’s Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. J Am Med Ass 2004;291:1701-1712. 8. Beral V. Million Women Study
Collaborators. Breast cancer and hormonereplacement therapy in the Million Women Study. Lancet 2003;362:419-427.
9. Haas JS, Kaplan CP, Gerstenberger EP, Kerlikowske K. Changes in the use of postmenopausal hormone replacement therapy after the publication of study results. Ann Intern Med 2004;140:184-188. 10. Bestul MB, McCollum M, Hansen
LB, Saseen JJ. Impact of the women’s health initiative trial results on hormone replacement therapy. Pharmacotherapy 2004;24:495-499. 11. Rozenbaum H. Relationships between
chemical structure and biological properties of progestogens. Am J Obstet Gynaecol 1982;142:719-724. 12. Kuhl H. Pharmacokinetics of
oestrogens and progestogens. Maturitas 1990; 12:171-197. 13. Schöler HFL, De Wachter AM.
Biological properties of 9,10-isomeric steroids. I. Progestational activity of 9ß,10 - steroids. Acta Endocrinol 1960;35:188-196.
14. Reerink EH, Schöler HFL, Westerhof P, Querido A, Kassenaar AAH, Diczfalusy E, Tillinger KC. A new class of hormonally active steroids. Nature 1960;186:168- 169.
15. Tausk M. A general summary of dydrogesterone, a derivative of retroprogesterone. In: Tausk M, editor. International Encyclopaedia
of Pharmacology and Therapeutics. Section 48. Pharmacology of the Endocrine System and Related Drugs: Progesterone, Progestational Drugs and Antifertility Drugs.Volume Pergamon Press: Oxford, New York, 1972:481.
16. Claasen V, Morsink L, De Wachter AM. Influence of dydrogesterone (6-dehydroretroprogesterone, Duphaston® on ovulation in the rat, rabbit and monkey. Acta Endocrinol 1971;67:551-562. 17. Marois M. Action d’un progestatif actif par voie buccale, la dydrogestérone, sur la come utérine de la lapine. Bulletin de L’Académie Nationale de Médecine 1962;146:324- 328.
18. Marois M. Absence de propriétés masculinisantes ou féminisantes d’un progestatif actif per os, la dydrogestérone, chez le rat male ou femelle adulte et chez le foetus de rat [The absence of masculinising or feminising properties of an orally active progestogen, dydrogesterone, in adult male and female rats and in rat foetuses]. Bulletin de L’ Académie Nationale de Médecine 1962;146:354-364.
19. Boris A, Stevenson RH, Timal T. Some studies on the endocrine properties of dydrogesterone. Steroids 1966;7:1- 10. 20. Lane G, Siddle N, Ryder TA, Pryse-Davies J, King RJB, Whitehead MI. Effects of dydrogesterone on the oestrogenized postmenopausal endometrium. Br J Obstet Gynaecol 1986;93:55-62.
21. Vomachka AJ, Paup DC, Coniglio LP, McManus MF, Clemens LG. Progestininduced pseudohermaphroditism in the female hamster. J Reprod Fert 1974;37:269- 276.
22. MacDonald GJ. Maintenance of pregnancy in ovariectomised rats with steroid analogues and the reproductive ability of progeny. Biol Reprod 1982;27:261-267.
23. Vermorken AJM, Sultan CH, Goos CMAA. Dydrogesterone has no
peripheral (anti)-androgenic properties. In Vivo 1987;1:167-172.
24. Schöler HFL, De Wachter AM. Evaluation of the androgenic properties of progestational compounds in the rat by the female foetal masculinisation test. Acta Endocrinol 1961;38:128-136.
25. Jost A. Maintien de la gestation chez la lapine par un stéréo-isomère voisin de la progestérone (6-déhydro-rétro- progesterone). Action sur le foetus. Acta Endocrinol 1963;43:539-544. 26. Suchowsky GK, Turolla E, Arcari
G. Studies of the so-called virilizing effects of steroids in female rat fetuses. Endocrinol 1967;80:255-262. 27. Schöler HFL. Maintenance of
pregnancy in spayed animals with 6-dehydroretro- progesterone, and masculinisation of the female foetus as a test for androgenic activity of progestational compounds. J Endocrinol 1962;24:15-16.
28. Wambach G, Helber A. Structure-affinity relationship of antimineralocorticoid active steroids. In: Agarwal MK, editor. Hormone antagonists. Berlin, New York: Walter de Gruyten and Company, 1982:293-305.
29. Verhaar HJJ, Damen CA, Duursma SA, Scheven BAA. A comparison of the action of progestins and estrogen on the growth and differentiation of normal adult human osteoblast-like cells in vitro. Bone 1994;15:307-311. 30. Englund DE, Johansson EDB. Oral
versus vaginal absorption of estradiol in postmenopausal women. Upsala J Med Sci 1981;86:297-307.
31. Fink BJ, Christensen MS. Bioavailability of estradiol and oestriol administered orally to oophorectomized women. Maturitas 1981;3:289-294.
32. Bolt HM. Metabolism of estrogens - natural and synthetic. Pharmacol Therapeutics 1979;12:155-181. 33. Stumpf PG. Pharmacokinetics of
estrogen. Obstet Gynecol 1990;75 (Suppl.):S9-S14.
34. van de Weijer PHM, Barentsen R, De Vries MH, Kenemans P. Relationship of estradiol levels to breakthrough bleeding during continuous combined hormone replacement therapy. Obstet Gynecol 1999;93:551-557.
35. Mashchak CA, Lobo RA, Dozono- Takano R, Eggena P, Nakamura RM, Brenner PF, Mishell DR Jr. Comparison of pharmacodynamic properties of various estrogen formulations. Am J Obstet Gynaecol 1982;144:511-518.
36. Archer DF, Fischer LA, Rich D, Schade GH, Schwartz S, Wittcoff H, Clark CSsr, Maloney K, Smith FO. Estrace® vs Premarin® for treatment of menopausal symptoms: dosage comparison study. Adv Ther 1992;9:21-31.
37. Schindler AE, Campagnoli C, Druckmann R, Huber J, Pasqualini JR, Schweppe KW, Thijssen JHH. Classification and pharmacology of progestins. Maturitas 2003;46(Suppl. 1):S7-S16.
38. Campagnoli C, Colombo P, De Aloysio D, Gambacciani M, Grazioli I, Nappi C, Serra G, Riccardo A. Positive effects on cardiovascular and breast metabolic markers of oral estradiol and dydrogesterone in comparison with transdermal estradiol and norethisterone acetate. Maturitas 2002;41:299-311.
39. Campagnoli C, Lesca L, Cantamessa C, Peris C. Long-term hormone replacement treatment in menopause: new choices, old apprehensions, recent findings. Maturitas 1993;18,21-46.
40. Siddle NC, Fraser D, Whitehead MI, Jesinger DK, Endacott J, Prescott P, Pryse- Davies J. Endometrial, physical and psychological effects of postmenopausal estrogen therapy with added dydrogesterone. Br J Obstet Gynaecol 1990;97:1101-1107. 41. Vermorken AJM, Sultan C, Goos
CMAA. Dydrogesterone has no peripheral (anti)-androgenic properties. In Vivo 1998;1:167-172.
42. Porter M, Penney G, Russell D, Russell E, Templeton A. A population based survey of women’s experience of the menopause. Br J Obstet Gynaecol 1996;103:1025-1028.
43. Kronenberg F. Hot flushes:
epidemiology and physiology. Ann N Y Acad Sci 1990;592:52-86.
44. Oldenhave A, Jaszmann LJB, Haspels AA, Everaerd WTAM. Impact of climacteric on well-being: a survey on 5213 women 39 to 60 years old. Am J Obstet Gynecol 1993;168:772-780.
45. Zweifel JE, O’Brian WH. A meta- analysis of the effect of hormone replacement therapy upon depressed mood. Psychoneuroendocrinol 1997;22:189-212.
46. Karlberg J, Mattsson L, Wiklund I. A quality of life perspective on who benefits from estradiol replacement therapy. Acta Obstet Gynecol Scandi 1999;74:367-372.
47. Daly E, Vessey M, Barlow D, Gray A, McPherson K, Roche M. Hormone replacement therapy in a risk-benefit perspective. Maturitas 1996;23:247-259. 48. Clinical Synthesis Panel on HRT.
Clinical synthesis conference: Hormone replacement therapy. Lancet 1999;354:152-155.
49. Kenemans P. Menopause, hormone replacement therapy and menopausal symptoms. J Epidemiol Biostat 1999;4:141-146.
50. Torgerson DJ, Reid DM. The pharmacoeconomics on hormone replacement therapy. Pharmacoeconomics 1999;1:9-16. 51. Amy JJ. Femoston®: effects on bone
and quality-of-life. Eur Menop J 1995;2(Suppl.):16-22.
52. Quereux C, Mijatovic V, Pigne A. Low- dose oestradiol plus dydrogesterone relieves climacteric symptoms and improves quality of life. Acta Obs Gyn Scand (submitted for publication). 53. Hänggi W, Birkhaeuser MH. A
new peroral estrogen/progestine combination for postmenopausal hormonal substitution: an open
72 73 multicentric field study. Maturitas
1993;16:111-122.
54. Kronenberg F, Fugh-Berman A. Complementary and alternative medicine for menopausal symptoms: a review of randomized, controlled trials. Ann Intern Med 2002;137:805-813. 55. North American Menopause Society.
Treatment of menopause-associated vasomotor symptoms: position statement of The North American Menopause Society. Menopause 2004;11:11-33.
56. Warnecke G. [Control of climacteric complaints by a phytopharmacon: Successful therapy with Cimicifuga mono-extract] [German]. Med Welt 1985;36:871-874.
57. Stoll W. [Phytopharmacon influences atrophic vaginal epithelium— doubleblind stud - Cimicifuga vs. estrogenic substances] [German]. Therapeutikon 1987;1:23-31.
58. Lehmann-Willenbrock E, Riedel HH. [Clinical and endocrinologic studies of the treatment of ovarian insufficiency manifestations following hysterectomy with intact adnexa] [German]. Zentralbl Gynakol 1998;110:611-618. 59. Unfer V, Casini ML, Costabile L,
Mignosa M, Gerli S, Di Renzo GC. Endometrial effects of long-term treatment with phytoestrogens: a randomized, doubleblind, placebo- controlled study. Fertil Steril 2004;82:145-148.
60. Stumpf WE, Sur M, Joshi SE. Estrogen target cells in the skin. Experientia 1976;30:196-198.
61. Bolognia JL, Braverman IM, Rousseau ME, Sarrel PM. Skin changes in menopause. Maturitas 1989;11:295- 304.
62. Fraser D, Padwick ML, Whitehead MI, Coffer A, King RJB. Presence of an oestradiol receptor-related protein in the skin: changes during the normal menstrual cycle. Br J Obstet Gynaecol 1991;98:1277-1282.
63. Castelo-Branco C, Durran M, Gonzales-Merlo J. Skin collagen
changes related to age and hormone replacement therapy. Maturitas 1992;15:113-119.
64. Aloia JF, McGowan DM, Vaswani AN, Ross P, Cohn SH. Relationship of menopause to skeletal and muscle mass. Am J Clin Nutr 1991;53:1378-1383. 65. Rauramo L, Punnonen R. The effect
of castration and peroral estrogen therapy on a woman’s skin. Ageing and Estrogens. Front Hormone Res Basel: Karger, 1973:48-54.
66. Dunn L, Damesyn M, Moore AA, Reuben DB, Greendale GA. Does estrogen prevent skin aging? Arch Dermatol 1997;133:399-342. 67. Brincat M, Moniz CF, Magos A,
de Trafford J, Studd JWW. Skin collagen changes in postmenopausal women receiving different regimes of estrogen therapy. Obstet Gynecol 1987;70:123-127.
68. Punnonen R, Vilska S, Rauramo L. Skinfold thickness and long-term postmenopausal hormone therapy. Maturitas 1984;5:259-262.
69. Meschia M, Bruschi F, Amicarelli F, Barbacini P, Monza G, Crosignani P. Transdermal hormone replacement therapy and skin in post-menopausal women: a placebo controlled study. J Am Menop Soc 1994;1:79-82. 70. Maheux R, Naud R, Rioux M,
Grenier R, Lamay A, Guy J, Langerin M. A randomised, double-blind, placebo-controlled study on the effect of conjugated estrogens on skin thickness. Am J Obstet Gynecol 1994;170:642-649.
71. Brincat MP. Hormone replacement therapy and the skin: beneficial effects: the case in favor of it. Acta Obstet Gynecol Scand 2000;79:244-249. 72. Sauerbronn AVD, Fonseca AM, Bagnoli
VR, Saldiva PH, Pinotti JA. The effects of systemic hormonal replacement therapy on the skin of postmenopausal women. Int J Gynecol Obstet 2000;68:35-41.
73. Youn CS, Kwon OS, Won CH, Hwang EJ, Park BJ, Eun HC, Chung JH. Effect
of pregnancy and menopause on facial wrinkling in women. Acta Derm Venereol 2003;83:419-424.
74. Rozenbaum H, Birkhäuser MH. Consensus propositions. In: Birkhäuser MH, Rozenbaum H, editors.
Menopause. European Consensus Development Conference. Montreux, Switzerland, 8-10 September 1995. Paris: Editions Eska 1996:293-303. 75. Sator MO, Nagele F, Sator P, Travica S,
Gruber D, Huber JC. Clinical profile of a new hormone replacement therapy containing 2 mg 17ß-estradiol and 10 mg dydrogesterone. Maturitas 2000;34:267-273.
76. Calaf Alsina J. Perception and use of local hormone
replacement therapy. Eur Menop J 1996;3(Suppl.):85-89.
77. Cardozo L. The role of oestrogens in urogynaecology: Low-dose therapy. In: Birkhäuser MH, Rozenbaum H, editors. Menopause. European Consensus Development Conference. Montreux, Switzerland, 8-10 September 1995. Paris: Editions Eska 1996:59-66.
78. Fantl JA, Cardozo L, McLish DK, and The Hormones and Urogenital Therapy Committee. Estrogen therapy in the management of urinary incontinence in postmenopausal women: a meta-analysis. First report of the Hormones and Urogenital Therapy Committee. Obstet Gynecol 1994;83:12-18.
79. Callantine MR, Martin PL, Bolding OT, Warner PO, Greaney MOjr. Micronized 17ß-estradiol for oral estrogen therapy in menopausal women. Obstet Gynecol 1975;46:37-41.
80. Te Velde ER, van Leusden HAIM. Hormonal treatment for the climacteric: alleviation of symptoms and prevention of postmenopausal disease. Lancet 1994;343:654-658. 81. Elia G, Bergman A. Estrogen effects
on the urethra: beneficial effects in women with genuine stress incontinence. Obstet Gynecol Surv 1993;48:509-517.
82. Nichols KC, Schenkel L, Benson H. 17ß-estradiol for postmenopausal estrogen replacement therapy. Obstet Gynecol Surv 1984;39(Suppl. 4):230-245. 83. Nilsson K, Heimer G. Low-dose 17
beta-oestradiol during maintenance therapy a pharmacokinetic and pharmacodynamic study. Maturitas 1995;21:33-38.
84. Gelfand M, Fugère P, Bissonnette F. Cardiovascular risk factors during sequentially combined 17ß-oestradiol and dydrogesterone (Femoston®); results from a one-year study in postmenopausal women. Maturitas 1997;26:125-132.
85. Cardozo L, Bachmann G, McClish D, Fonda D, Birgerson L. Meta- analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: second report of the Hormones and Urogenital Therapy Committee. Obstet Gynecol 1998;92:722-727. 86. Graziottin A. HRT: the woman’s
perspective. Int J Gynecol Obstet 1996;52(Suppl. 1):S1-S6.
87. Lachowsky M. Urinary problems around the menopause; emotional and psychological consequences; can we help our patients to cope with them? Maturitas 2000;34(Suppl. 1):S25-S27. 88. Privette M, Cade R, Peterson J, Mars D. Prevention of recurrent urinary tract infections in postmenopausal women. Nephron 1988;50:24-27. 89. Calaf Alsina J. The role of oestrogens
in urogynaecology: High-dose therapy. In: Birkhäuser MH, Rozenbaum H, editors. Menopause. European Consensus Development Conference. Montreux, Switzerland, 8-10 September 1995. Paris: Editions Eska 1996:51-58.
90. Kok ALM, Burger CW, van de Weijer PHM, Voetberg GA, Peters-Muller ERA, Kenemans P. Micturition complaints in postmenopausal women treated with continuously combined hormone replacement therapy: a prospective study. Maturitas 1999;31:143-149.
91. Tosteson ANA, Gabriel SE, Kneeland TS, Moncur MM, Manganiello PD, Schiff I, Ettinger B, Melton LJ 3rd. Has the impact of hormone replacement therapy on health- related quality of life been
undervalued? J Womens Health Gend Based Med 2000;9:119-130.
92. Kirchengast S, Gruber D, Sator M, Hartmann B, Knogler W, Huber J. Menopause-associated difference s in female fat patterning estimated by dualenergy X-ray absorptiometry. Ann Hum Biol 1997;24:45-54.
93. van Seumeren I. Weight gain and hormone replacement therapy: are women’s fears justified? Maturitas 2000;34(Suppl. 1):S3-S8.
94. Crook D, Godsland IF, Hull J, Stevenson JC. Hormone replacement therapy with dydrogesterone and 17ß-oestradiol: effects on serum lipoproteins and glucose tolerance during 24 month follow up. Br J Obstet Gynaecol 1997;104:298-304. 95. The Writing Group for the PEPI
Trial. Effects of estrogen or estrogen/ progestin regimens on heart disease risk factors in postmenopausal women. The postmenopausal estrogen/progestin interventions (PEPI) trial. J Am Med Ass 1995;273:199-208.
96. van der Mooren MJ, Demacker PNM, Thomas CMG, Borm GF, Rolland R. A 2-year study on the beneficial effects of 17ß-oestradiol-dydrogesterone therapy on serum lipoproteins and Lp(a) in postmenopausal women: no additional unfavourable effects of dydrogesterone. Eur J Obstet Gynecol Reprod Biol 1993;52:117-123.
97. Hänggi W, Lippuner K, Riesen W, Jaeger P, Birkhäuser MH. Long term influence of different postmenopausal hormone replacement regimes on serum lipids and lipoprotein(a): a randomized study. Br J Obstet Gynaecol 1997;104:708-717. 98. Hänggi W, Lippuner K, Jaeger
P, Birkhäuser MH, Horber FF.
Differential impact of conventional oral or transdermal hormone replacement therapy or tibolone on body composition in postmenopausal women. Clin Endocrinol 1998;48:691- 699.
99. Cummings SR, Black DM, Newitt MC, Browner W, Cauley J, Ensrud K, Genant HK, Palermo L, Scott J, Vogt TM. Bone density at various sites for prediction of hip fractures. Lancet 1993;341:72-75. 100. Looker AC, Orwoll ES, Johnston
CC, Jr., Lindsay RL, Wahner HW, Dunn WL, Calvo MS, Harris TB, Heyse SP. Prevalence of low femoral bone density in older U.S. adults from NHANES III. J Bone Miner Res 1997;12:1761-1768.
101. Anonymous. NORA (National Osteoporosis Risk Assessment) study sounds alarm on risk of osteoporotic fractures. Dis Manag Advis 2002;8:17- 21.
102. Gill JM, Hoffman MK. Prevention and treatment of osteoporosis in primary care offices. J Women’s Health (Larchmt) 2003;12:473-480.
103. Truumees E. Medical consequences of osteoporotic vertebral compression fractures. Instr Course Lect
2003;52:551-558
104. Jalava T, Sarna S, Pylkkanen L, Mawer B, Kanis JA, Selby P, Davies M, Adams J, Francis RM, Robinson J, McCloskey E. Association between vertebral fracture and increased mortality in osteoporotic patients. J Bone Miner Res 2003;18:1254-1260.
105. Melton IJI, Lane AW, Cooper C et al. Hip fractures in the elderly: a worldwide projection. Osteop Int 1993;3:113-119.
106. Cooper C, Atkinson EJ, Jacobsen SJ, O’Fallon WM, Melton LJ 3rd. Population-based study of survival after osteoporotic fractures. Am J Epidemiol 1993;137:1001-1005.
107. Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA. Mortality after all major types of osteoporotic
fracture in men and women: An Observational Study. Lancet 1999;353:878-882.
108. Phillips K, Glendon G, Knight JA. Putting the risk of breast cancer in perspective. N Engl J Med 1999;340:141- 144.
109. Roberts SE, Goldacre MJ. Time trends and demography of mortality after fractured neck of femur in an English population 1968-98. Br Med J 2003;327:771-775.
110. Wehren LE. The epidemiology of osteoporosis and fractures in geriatric medicine. Clin Geriatr Med 2003;19:245- 258.
111. Consensus Development Conference. Diagnosis, prophylaxis, and treatment of osteoporosis. Am Med J 1993;94:646- 650.
112. Riis BJ. How should HRT be used in the prevention and treatment of osteoporosis? In: Birkhäuser MH, Rozenbaum H, editors. Menopause. European Consensus Development Conference. Montreux, Switzerland, 8-10 September 1995. Paris: Editions Eska 1996:111-116.
113. Wells G, Tugwell P, Shea B, Guyatt G, Peterson J, Zytaruk N, Robinson V, Henry D, O’Connell D, Cranney A, The Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group. Meta-analyses of therapies for postmenopausal osteoporosis. V. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. Endocr Rev 2002;23:529-539.
114. World Health Organisation. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO Technical Report Series 843. Geneva 1994.
115. Kanis JA, Johnell O, Gullberg B, Allander E, Dilsen G, Gennari C, Vaz AAL, Lyritis GP, Mazzuoli G, Miravet L, Passeri M, Cano RP, Ribot C. Evidence for efficacy of drugs affecting bone metabolism in
preventing hip fracture. Br Med J 1992;305:1124-1128.
116. Kiel DP, Felson DT, Anderson JJ, Wilson PWF, Moskowitz MA. Hip fracture and the use of estrogens in postmenopausal women: the Framingham study. N Engl J Med 1987;317:1169-1174.
117. Mosekilde L, Beck-Nielsen H, Sorensen OH, Nielsen SP, Charles P, Vestergaard P, Hermann AP, Gram J, Hansen TB, Abrahamsen B, Ebbesen EN, Stilgren L, Jensen LB, Brot C, Hansen B, Tofteng CL, Eiken P, Kolthoff N. Hormonal replacement therapy reduces forearm fracture incidence in recent postmenopausal women. Results of the Danish Osteoporosis Prevention Study. Maturitas 2002;42(Suppl. 1):S59-S71. 118. Cauley JA, Robbins J, Chen Z,
Cummings SR, Jackson RD, LaCroix AZ, LeBoff M, Lewis CE, McGowan J, Neuner J, Pettinger M, Stefanick ML, Wactawski-Wende J, Watts NB. Women’s Health Initiative Investigators Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women’s Health Initiative randomized trial. J Am Med Ass 2003;290:1729-1738.
119. Hänggi W, Lippuner K, Casez J-P, Birkhäuser MH, Jaeger P. Prevention of postmenopausal bone loss using conventional hormone replacement therapy or ORG OD14. Schweiz Med Wochenschr 1993;123(Suppl. 50/ II):A513.
120. Lippuner K, Haenggi W, Birkhaeuser H, Casez J-P, Jaeger P. Prevention of postmenopausal bone loss using tibolone or conventional peroral or transdermal hormone replacement therapy with 17ß-estradiol and dydrogesterone. J Bone Mineral Res 1997;12:806-812.
121. De Valk-De Roo GW, Netelenbos JC, Peters-Muller IRA, Voetberg GA, van de Weijer PHM, Bouman AA, Popp- Snijders C, Kenemans P. Continuously combined hormone replacement
76 77 therapy and bone turnover: the
influence of dydrogesterone dose, smoking and initial degree of bone turnover. Maturitas 1997;28:153-162. 122. Ettinger B, Genant HK, Steiger P, Madvig
P. Low dosage micronized 17ß-estradiol prevents bone loss in postmenopausal women. Am J Obstet Gynecol 1992;166:479-488.
123. Studd J, Panay N, Zamblera D, Leather AT. HRT and long-term compliance: The efficacy and safety of Menorest®. Int J Gynecol Obstet 1996;52(Suppl. 1):21-25.
124. Voetberg GA, Netelenbos JC, Kenemans P, Peters-Muller ERA, van de Weijer PHM. Estrogen replacement therapy continuously combined with four different dosages of dydrogesterone: effect on calcium and lipid metabolism. J Clin Endocrinol Metabol 1994;79:1465- 1469.
125. Lees B, Pugh M, Siddle N, Stevenson JC. Changes in bone density in women starting hormone replacement therapy compared with those in women already established on hormone replacement therapy. Osteop Int 1995;5:344-348.
126. van Hoof HJC, van der Mooren MJ, Swinkels LMJW, Rolland R, Benraad TJ. Hormone replacement therapy increases serum
1,25-dihydroxyvitamin D: a 2-year prospective study. Calcified Tissue Int 1994;55:417-419.
127. Gambacciani M, Ciaponi M, Cappagli B, Piaggesi L, Benussi C, Piccheti S, Genazzani AR. Long-term effects of cyclic combined conjugated estrogens and dydrogesterone in postmenopausal women. In: Wren BG, editor. Progress in the Management of the Menopause. The Proceedings of the 8th Congress on the Menopause. Sydney, Australia, November 1996. New York, London: Parthenon Publishing 1997:432-437. 128. Stevenson JC, Teter P, Lees B.
17ß-estradiol (1 mg/day) continuously
combined with dydrogesterone (5, 10 or 20 mg/day) increases bone mineral density in postmenopausal women. Maturitas 2001;38:197-203.
129. Quigley MET, Martin PL, Burnier AM, Brooks P. Estrogen therapy arrests bone loss in elderly women. Am J Obstet Gynecol 1987;156:1516-1523. 130. Marx CW, Dailey GB, Cheney C, Vint
VC, Muchmore DB. Do estrogens improve bone mineral density in osteoporotic women over age 65? J Bone Mineral Res 1992;7:1275-1279. 131 Naessén T, Persson I, Adami HO,
Bergström R, Bergkvist L. Hormone replacement therapy and the risk for first time hip fracture. A prospective,